Hematology and Medical Oncology, Centre Hospitalier de l'Université de Montréal, Montreal, Canada.
Expert Opin Biol Ther. 2011 Aug;11(8):1091-7. doi: 10.1517/14712598.2011.592490. Epub 2011 Jun 21.
Immunotherapy as a possible therapeutic option for cancer has been of great importance due to the innovative development of vaccines. Various molecules have been tested and emepepimut-S (Biomira Liposomal Peptide 25 (BLP 25)) has emerged as an option, particularly in lung cancer.
A PubMed literature and ClinicalTrials.gov search was conducted using the terms: emepepimut, BLP25, NSCLC, cancer immunotherapy, cancer vaccine and MUC1. This review covers how emepepimut-S acts against the mucin 1 (MUC1) tumor-associated antigen producing a cellular immune response against the cells that express MUC1 and the most important clinical data available that led to the ongoing Phase III trial.
The results obtained in the Phase I/II trials are promising, showing a favorable toxicity with a benefit in survival in NSCLC patients. As future trials develop, demonstration of the long-term survival benefit, understanding of the various mechanisms of immune response initiated by the drug and the selection of patients that will highly benefit from the immunotherapy will be elucidated. The safety and extension in survival makes emepepimut-S a very interesting drug and could, therefore, offer a possibility of treatment and maintenance, particularly for good performance status patients with locally advanced NSCLC.
免疫疗法作为癌症的一种可能的治疗选择，由于疫苗的创新发展，变得非常重要。已经测试了各种分子，其中 emepepimut-S（Biomira 脂质体肽 25（BLP 25））是一种选择，特别是在肺癌中。
使用术语“emepepimut、BLP25、非小细胞肺癌、癌症免疫疗法、癌症疫苗和 MUC1”在 PubMed 文献和 ClinicalTrials.gov 上进行了搜索。这篇综述涵盖了 emepepimut-S 如何针对粘蛋白 1（MUC1）肿瘤相关抗原发挥作用，针对表达 MUC1 的细胞产生细胞免疫反应，以及导致正在进行的 III 期试验的最重要的现有临床数据。
I 期/II 期试验的结果很有希望，显示出非小细胞肺癌患者具有良好的生存获益和毒性。随着未来试验的发展，将阐明长期生存获益的证明、药物引发的各种免疫反应机制的理解以及从免疫疗法中获益最大的患者的选择。安全性和生存获益的延长使 emepepimut-S 成为一种非常有趣的药物，因此可以提供治疗和维持的可能性，特别是对于局部晚期非小细胞肺癌且体能状态良好的患者。
